$2.35 Billion is the total value of Avidity Partners Management LP's 85 reported holdings in Q2 2024. The portfolio turnover from Q1 2024 to Q2 2024 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CI | THE CIGNA GROUP | $60,990,165 | -9.0% | 184,500 | 0.0% | 2.59% | +19.9% | |
| GKOS | GLAUKOS CORP | $26,510,400 | +25.5% | 224,000 | 0.0% | 1.13% | +65.3% | |
| PCVX | VAXCYTE INC | $21,444,840 | +10.5% | 284,000 | 0.0% | 0.91% | +45.5% | |
| NEUMORA THERAPEUTICS INC. | $17,694,000 | -28.5% | 1,800,000 | 0.0% | 0.75% | -5.8% | ||
| RGNX | REGENXBIO INC | $15,210,749 | -44.5% | 1,300,064 | 0.0% | 0.65% | -26.8% | |
| PRVA | PRIVIA HEALTH GROUP INC | $13,281,796 | -11.3% | 764,200 | 0.0% | 0.56% | +16.8% | |
| IMNM | IMMUNOME INC | $10,574,081 | -51.0% | 873,891 | 0.0% | 0.45% | -35.4% | |
| IMUX | IMMUNIC INC | $9,882,299 | -15.9% | 8,902,972 | 0.0% | 0.42% | +10.8% | |
| CLXPF | CYBIN INC | $9,453,564 | -34.5% | 34,884,000 | 0.0% | 0.40% | -13.5% | |
| SYROS PHARMACEUTICALS INC | $8,635,456 | -3.6% | 1,673,538 | 0.0% | 0.37% | +27.0% | ||
| KZR | KEZAR LIFE SCIENCES INC | $3,015,600 | -33.5% | 5,026,000 | 0.0% | 0.13% | -12.3% | |
| SCYX | SCYNEXIS INC | $2,897,456 | +36.1% | 1,448,728 | 0.0% | 0.12% | +78.3% | |
| HYPERFINE INC | $1,009,951 | -15.0% | 1,188,178 | 0.0% | 0.04% | +13.2% | ||
| CAREMAX INCcl a new | $59,148 | -42.1% | 21,200 | 0.0% | 0.00% | 0.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2024-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC | 18 | Q2 2024 | 4.6% |
| ARVINAS INC | 17 | Q2 2024 | 4.9% |
| SYNDAX PHARMACEUTICALS INC | 17 | Q2 2024 | 3.2% |
| NATERA INC | 16 | Q2 2024 | 3.5% |
| IDEAYA BIOSCIENCES INC | 16 | Q2 2024 | 2.5% |
| ABBVIE INC | 15 | Q2 2024 | 9.7% |
| AVANTOR INC | 14 | Q2 2024 | 6.0% |
| ZENTALIS PHARMACEUTICALS INC | 14 | Q3 2023 | 4.8% |
| IMMUNOCORE HLDGS PLC | 14 | Q2 2024 | 2.0% |
| ALPINE IMMUNE SCIENCES INC | 14 | Q1 2024 | 1.5% |
View Avidity Partners Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Context Therapeutics Inc. | May 13, 2024 | 7,500,431 | 9.9% |
| ARCA biopharma, Inc. | April 09, 2024 | 1,000,000 | 6.9% |
| Jasper Therapeutics, Inc. | March 27, 2024 | 760,000 | 5.1% |
| Altimmune, Inc.Sold out | February 14, 2024 | 0 | 0.0% |
| IDEAYA Biosciences, Inc. | February 14, 2024 | 1,520,000 | 2.4% |
| Karyopharm Therapeutics Inc. | February 14, 2024 | 11,188,743 | 9.5% |
| Kezar Life Sciences, Inc. | February 14, 2024 | 5,025,454 | 6.9% |
| Akero Therapeutics, Inc. | February 13, 2024 | 235,000 | 0.4% |
| ARVINAS, INC. | February 13, 2024 | 2,985,117 | 4.4% |
| Cyteir Therapeutics, Inc.Sold out | February 13, 2024 | 0 | 0.0% |
View Avidity Partners Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-13 |
| SC 13G | 2024-04-09 |
| SC 13G | 2024-03-27 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avidity Partners Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.